EA200800663A1 - Способ и средство профилактики и лечения нарушенного дыхания во время сна - Google Patents

Способ и средство профилактики и лечения нарушенного дыхания во время сна

Info

Publication number
EA200800663A1
EA200800663A1 EA200800663A EA200800663A EA200800663A1 EA 200800663 A1 EA200800663 A1 EA 200800663A1 EA 200800663 A EA200800663 A EA 200800663A EA 200800663 A EA200800663 A EA 200800663A EA 200800663 A1 EA200800663 A1 EA 200800663A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osa
csa
snoring
prevention
treatment
Prior art date
Application number
EA200800663A
Other languages
English (en)
Inventor
Ян Хеднер
Лудгер Гроте
Кай Стенлёф
Original Assignee
Сириусайенс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сириусайенс Аб filed Critical Сириусайенс Аб
Publication of EA200800663A1 publication Critical patent/EA200800663A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ лечения или профилактики храпа, обструктивного апноэ во время сна (OSA) и/или центрального апноэ во время сна (CSA) включает введение пациенту фармакологически эффективного количества соли ацетилгомотаурина (АсНТ), такой как акампросат кальция (СА). Также раскрыто применение АсНТ и СА для изготовления лекарственного средства для лечения или профилактики храпа, OSA и/или CSA и диагностического устройства, набора или композиции; защитный пластырь, содержащий АсНТ или СА; и фармацевтическая композиция, содержащая АсНТ или СА, и агент, способный облегчать эффекты храпа, OSA и/или CSA, в комбинированных количествах, эффективных в лечении храпа, OSA и/или CSA, и носитель.
EA200800663A 2005-09-16 2006-09-04 Способ и средство профилактики и лечения нарушенного дыхания во время сна EA200800663A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502044 2005-09-16
PCT/SE2006/001010 WO2007032720A1 (en) 2005-09-16 2006-09-04 Method and means of preventing and treating sleep disordered breathing

Publications (1)

Publication Number Publication Date
EA200800663A1 true EA200800663A1 (ru) 2008-10-30

Family

ID=37865217

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800663A EA200800663A1 (ru) 2005-09-16 2006-09-04 Способ и средство профилактики и лечения нарушенного дыхания во время сна

Country Status (11)

Country Link
US (1) US20080261931A1 (ru)
EP (1) EP1928445A1 (ru)
JP (1) JP2009508854A (ru)
KR (1) KR20080059208A (ru)
CN (1) CN101291663A (ru)
AU (1) AU2006291581A1 (ru)
CA (1) CA2622721A1 (ru)
EA (1) EA200800663A1 (ru)
IL (1) IL190097A0 (ru)
WO (1) WO2007032720A1 (ru)
ZA (1) ZA200802415B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217564A1 (en) 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
KR20120101588A (ko) * 2010-01-07 2012-09-13 비버스 인크. 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
EP2672972B1 (en) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
JP6514420B2 (ja) 2016-05-11 2019-05-15 ヘドナー，ヤン 睡眠時無呼吸の処置のためのスルチアム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20020102525A1 (en) * 2001-01-31 2002-08-01 Trainease, Inc. System and method for coordinating the selection and delivery of educational services
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
SE0400378D0 (sv) * 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet

Also Published As

Publication number Publication date
CA2622721A1 (en) 2007-03-22
CN101291663A (zh) 2008-10-22
WO2007032720A1 (en) 2007-03-22
AU2006291581A1 (en) 2007-03-22
IL190097A0 (en) 2008-11-03
KR20080059208A (ko) 2008-06-26
US20080261931A1 (en) 2008-10-23
ZA200802415B (en) 2008-12-31
EP1928445A1 (en) 2008-06-11
JP2009508854A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
DE602005010213D1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CA2434484A1 (en) Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
RS20050344A (en) Treatment for hemorrhagic shock
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
TW200806299A (en) Treatment of pain
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
NZ544645A (en) Use of calcitonin in osteoarthritis
WO2011041632A3 (en) Combination therapies for the treatment of obesity
EA201000855A1 (ru) Способ и средства для достижения бронхиальной релаксации
WO2010045417A3 (en) Combination therapies for the treatment of obesity
CA2632207C (en) Use of calcitonin for the treatment of ra
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
MX2009011900A (es) Curacion de herida diabetica.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
WO2010045522A3 (en) Combination therapies for the treatment of obesity
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis